Compare DoorDash Inc (DASH) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Incyte Corporation — how do they compare? DoorDash Inc trades at $192.28 (market cap $83.07B), while Incyte Corporation trades at $112.75 (market cap $22.85B). The key difference: DoorDash Inc is far larger — about 3.6× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Incyte Corporation for 33 Days on average.
| DASH | INCY | |
|---|---|---|
Market Cap | $83.07B | $22.85B |
Volume | 3,242,567 | 1,927,029 |
Sector | Media | Health |
52-Week High | $275.44 | $129.93 |
52-Week Low | $146.60 | $83.80 |
Typical Hold Time | 59 Days | 33 Days |
Enterprise Value | $81.03B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with strong analyst support showing 75% buy ratings and a $255.80 consensus price target. The company demonstrates robust revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent innovations include AI-powered text ordering and drone delivery expansion, while technical indicators show the stock trading near key support at $190 with overall bullish momentum.
DoorDash presents a compelling growth story with expanding margins and strategic initiatives, though elevated valuation multiples (P/E 100.13) and recent earnings misses warrant caution. The stock offers 34% upside to analyst targets but faces regulatory scrutiny and competitive pressures in the food delivery space. Positive cash flow trends and institutional support provide fundamental strength despite near-term volatility risks.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
